TCA
AQST icon

Transcend Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Transcend Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
31,511
-6,417
-17% -$27K 0.01% 797
2026
Q1 		$157K Buy
+37,928
New +$154K 0.01% 700

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Transcend Capital Advisors's AQST Position: Q2 2026 in Review

Transcend Capital Advisors reduced its Aquestive Therapeutics (AQST) stake by 17% in Q2 2026, selling an estimated $27K and leaving 31,511 shares worth $131K. The position accounts for 0.01% of the portfolio, ranked #797.

Transcend Capital Advisors first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. The position peaked at $157K in Q1 2026. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Transcend Capital Advisors held 31,511 shares of Aquestive Therapeutics worth $131K as of Q2 2026.
  • Transcend Capital Advisors sold 6,417 Aquestive Therapeutics shares in Q2 2026, an estimated $27K.
  • Aquestive Therapeutics made up 0.01% of Transcend Capital Advisors's portfolio in Q2 2026, its #797 holding.
  • Transcend Capital Advisors first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Transcend Capital Advisors's Aquestive Therapeutics position peaked at $157K in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.